Philadelphia Antitrust Litigation Lawyers

Antitrust laws were enacted to protect U.S. consumers and businesses from anti-competitive and monopolistic conduct that threatens our free and open markets, the foundation of a vibrant economy. Increasingly, pharmaceutical companies use patent litigation, and collusive settlements, to disrupt fair and open competition, particularly by delaying the market entry of cheaper generic drugs, the availability of which Congress has set as a priority since at least the enactment of the Hatch-Waxman Act in 1984.

Pay-For-Delay & Reverse Payment Settlements

Blockbuster branded drug manufacturers all too often attempt to unlawfully extend their exclusivity in the marketplace by suing generic drug manufacturers who seek to bring cheaper generic drugs into the market. “Reverse payments” refers to unlawful settlements in which the brand company pays the generic challenger -whether in monetary or non-monetary form - to delay entry of a generic into the market. Such settlements make no economic sense except as a form of unlawful payment not to compete. Since the U.S. Supreme Court’s ruling in FTC v. Actavis in 2013, such settlements can violate the antitrust laws, and injured purchasers can now recover the ill-gotten gains of such conduct.

Leading Consumer Class Action Lawyers

Golomb & Honik, P.C. has recovered over $1 billion in settlements and verdicts for our clients in both class action and individual litigation. We are not afraid to take on the nations largest corporations and have done so for decades. With our proven track record and dedicated team of experienced attorneys, you can be sure that your case will receive the tenacious representation that it deserves.

We are proud to provide all of our prospective clients with a complimentary case consultation so that we can discuss how we may be able to assist you. If you think you may have a case, contact our Philadelphia law firm today at (215) 278-4449.